<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ochirbat Dagvadorj</style></author><author><style face="normal" font="default" size="100%">Javkhlan Bold</style></author><author><style face="normal" font="default" size="100%">Tserendagva Dalkh</style></author><author><style face="normal" font="default" size="100%">Selenge Erdenechimeg</style></author><author><style face="normal" font="default" size="100%">Bold Sharav</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Re-examining Crude Drugs used in the Treatment of COVID-19 from Ancient Medical Books</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ancient medical books</style></keyword><keyword><style  face="normal" font="default" size="100%">Common cold</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza</style></keyword><keyword><style  face="normal" font="default" size="100%">Mana-4</style></keyword><keyword><style  face="normal" font="default" size="100%">Norov-7</style></keyword><keyword><style  face="normal" font="default" size="100%">Traditional medicine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">327-330</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Purpose:&lt;/strong&gt; Research ancient medical books to find the medicinal ingredients used in the two most widely used recipes for treating COVID-19. &lt;strong&gt;Research materials: &lt;/strong&gt;1. The following materials were used in the study. Including: Lamyn gegeen Luvsandanzanjantsan (1649-1704). “Man ngag bdud rtsi zegs ma.” Wooden printing block with Tibetan script. 2. Toin Jambaldorj (1792-1855). Gso byed bdud rtsi'i 'khrul med ngos 'dzin bzo rig me long du rnam par shar ba mdzes mtshar mig rgyan zhes bya ba bzhugs so. Wooden printing block with Tibetan script.&lt;strong&gt; Research Methods: &lt;/strong&gt;Methods of textual analysis for ancient books and checklist methods were used in the study. &lt;strong&gt;Conclusion:&lt;/strong&gt; The most effective and most widely used drugs for the treatment of COVID-19 were Mana-4 and Norov-7 decoctions. The source of these two decoctions is Lamyn gegeen Luvsandanzanjantsan’s (1649-1704) book “Man ngag bdud rtsi zegs ma”. This book was one of the main textbooks at the Medical School established in Mongolia in 1685. The traditional medicinal indications and usages of the 7 medicinal crude drugs included in the composition of Mana-4 and Norov-7 decoctions were studied in detail in Toin Jambaldorj’s book “Beautiful Marvelous Eye Ornament.” Apart from these 7 medicinal crude drugs, 6 medicinal crude drugs have the effect of treating influenza and influenza-like illnesses according to modern medical theory. Therefore, it has been established that Mana- 4 and Norov-7 decoctions have the effect of treating infectious febrile disorders accompanied by cold chills and shivering, preliminary stages of influenza, and open up bodily pores and induce sweat.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">327</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Ochirbat Dagvadorj&lt;sup&gt;1&lt;/sup&gt; , Javkhlan Bold&lt;sup&gt;1&lt;/sup&gt;, Tserendagva Dalkh&lt;sup&gt;1&lt;/sup&gt;, Selenge Erdenechimeg&lt;sup&gt;2&lt;/sup&gt;, Bold Sharav&lt;sup&gt;2,3&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Mongolian National University of Medical Sciences, Post Box 48/111, Ulaanbaatar city 14210, Mongolia&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Mongolian University of Pharmaceutical Sciences PO-37, Box-59, Ulaanbaatar 18080, Mongolia&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;“Ach” Medical University, Peace Avenue, Ulaanbaatar 18101&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsaba B.M</style></author><author><style face="normal" font="default" size="100%">Makhoahle P.M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bacteriological Profile of Clinical Isolates from COVID-19 Hospitalised and Non-Hospitalised Patients in Bloemfontein</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Patients</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">67-75</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The COVID-19 literature is limited regarding bacterial infections. If bacterial infections drive mortality in respiratory viruses, this has clear implications for patient management. To address this limited literature problem, we review current knowledge on bacterial infections in COVID-19, assess information from past viral respiratory pandemics, and determine the most prevalent infections. We also study antibiotic misuse during the COVID-19 pandemic. The findings of this study conclude that there is a need to consider presence or absence of bacterial infection in COVID-19 management. Early determination and antibiotic treatment are of importance, however not all patients who are tested for COVID -19 are also tested for bacterial infections which may exacerbate the disease. Physicians utilised antibiotics as a treatment for COVID -19 for various reasons, this posed a risk of antibiotic overuse and antimicrobial resistance when administered in patients with no bacterial infection. While lack of access to antibiotics could be dangerous in the same vein as its misuse, it is of importance to ensure that these life-saving agents are preserved and used with utmost care.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">67</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Matsaba B.M&lt;sup&gt;1,2 &lt;/sup&gt;and Makhoahle P.M&lt;sup&gt;1&lt;/sup&gt;,*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Health and Environmental Sciences, Department of Health Sciences, Biomedical Technology/Medical Laboratory Sciences, Central University of Technology, Free State, SOUTH AFRICA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;PathCare Laboratory-Bloemfontein, SOUTH AFRICA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Retno Budiarti</style></author><author><style face="normal" font="default" size="100%">Ediono</style></author><author><style face="normal" font="default" size="100%">Muhammad Miftahussurur</style></author><author><style face="normal" font="default" size="100%">Abdulloh Machin</style></author><author><style face="normal" font="default" size="100%">Mochammad Wijdan Rosyich</style></author><author><style face="normal" font="default" size="100%">Ayu Imamatun Nisa</style></author><author><style face="normal" font="default" size="100%">Fatimatuzzahro</style></author><author><style face="normal" font="default" size="100%">Nila Novia Putri</style></author><author><style face="normal" font="default" size="100%">Muhammad Ja’far Shodiq</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Biomarker Profiles Associated with Covid-19 Mortality in East Java, Indonesia: A Tertiary Care Hospital Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomarker</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">689-694</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Objective:&lt;/strong&gt; This study aimed to compare the most useful biomarkers for predicting prognosis and response to therapy in COVID-19 patients. &lt;strong&gt;Material and Methods:&lt;/strong&gt; This quantitative study involved 639 patients who were hospitalized with COVID-19 infection. Patients without any biochemical marker result; patients referred to another hospital; and peripheral oxygen levels measured using oxygen supplementation were excluded from the study. &lt;strong&gt;Results: &lt;/strong&gt;There was a statistically significant difference in terms of demographics, vital signs on admission, and laboratory parameters. The risk of mortality in COVID-19 is significantly influenced by c-reactive protein (CRP) and interleukin-6 (IL-6) levels (p-value &amp;lt;0.05). &lt;strong&gt;Conclusion:&lt;/strong&gt; Findings revealed these biomarkers could help the future development of more personalized treatment and diagnostic approaches.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">689</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Retno Budiarti&lt;sup&gt;1&lt;/sup&gt;*, Ediono&lt;sup&gt;2&lt;/sup&gt;, Muhammad Miftahussurur&lt;sup&gt;3,4&lt;/sup&gt;, Abdulloh Machin&lt;sup&gt;5,7&lt;/sup&gt;, Wiwin Is Effendi&lt;sup&gt;5,6&lt;/sup&gt;, Mochammad Wijdan Rosyich&lt;sup&gt;7&lt;/sup&gt;, Ayu Imamatun Nisa’&lt;sup&gt;8&lt;/sup&gt;, Fatimatuzzahro’&lt;sup&gt;8&lt;/sup&gt;, Nila Novia Putri&lt;sup&gt;7&lt;/sup&gt;, Muhammad Ja’far Shodiq&lt;sup&gt;7&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Microbiology, Faculty of Medicine, Hang Tuah University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Pulmonology Department, Naval Hospital, RSAL Dr. Ramelan, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine / Dr. Soetomo Teaching Hospital, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Helicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;5&lt;/sup&gt;Infectious Hospital, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;7&lt;/sup&gt;Neurology Department, Faculty of Medicine / Dr. Soetomo Teaching Hospital, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;8&lt;/sup&gt;Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Indra Sampe Parimba</style></author><author><style face="normal" font="default" size="100%">Arief Bakhtiar</style></author><author><style face="normal" font="default" size="100%">Soedarsono Soedarsono</style></author><author><style face="normal" font="default" size="100%">Riyanarto Sarno</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Effectiveness of Armpit Sweat Odor with COVID-19 Detection Device for Detecting COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Armpit sweat odor</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 detection device</style></keyword><keyword><style  face="normal" font="default" size="100%">RT-PCR</style></keyword><keyword><style  face="normal" font="default" size="100%">VOC</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">691-697</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Coronavirus disease 2019 (COVID-19) is a disease caused by the SARS-CoV-2 virus. Diagnosis and screening for COVID-19 are crucial in controlling the disease. RT-PCR is used for diagnosis. However, this test is high-risk, time-consuming, and expensive. There is a need for specific non-invasive biomarkers to detect COVID-19 rapidly. Volatile organic compounds (VOCs) produced by the human body can be used to depict metabolic conditions. A COVID-19 detection device is an electronic device designed to differentiate and detect odors. This study aims to assess the effectiveness of armpit sweat odor with a COVID-19 detection device to detect COVID-19. This study was an observational analytic study with a cross-sectional design conducted on COVID-19 and non-COVID-19 patients in the special isolation ward of Dr. Soetomo Hospital and the outpatient clinic of the Indonesian Navy Hospital during April 2021-December 2021. COVID-19 examination using armpit sweat odor with a COVID-19 detection device. The results of the COVID-19 detection device and RT-PCR were then compared using the McNemar test. The general characteristics of the 168 subjects (81 COVID-19 patients, 87 non-COVID-19 patients) showed that the most common gender was male with the most common comorbidities being hypertension and diabetes mellitus. The results of the diagnostic test showed sensitivity and specificity of 88.9% and 97.7%, respectively with accuracy of 93.45%. The McNemar test showed no significant difference with the RT-PCR results. The results of RT-PCR were not different from the results of armpit sweat odor using COVID-19 detection device.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">691</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Indra Sampe Parimba&lt;sup&gt;1&lt;/sup&gt;, Arief Bakhtiar&lt;sup&gt;1&lt;/sup&gt;*, Soedarsono Soedarsono&lt;sup&gt;1&lt;/sup&gt;, Riyanarto Sarno&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Dr. Soetomo General Hospital Surabaya, Airlangga University INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Informatics, Faculty of Intelligent Electrical and Informatics Technology, Institut Teknologi Sepuluh Nopember (ITS) Surabaya INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prafa Alif Rahmawan</style></author><author><style face="normal" font="default" size="100%">Yetti Hernaningsih</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Natural Compounds in Clot Waveform Analysis and D-Dimer Modulation: Implications for COVID-19 Diagnosis and Prognosis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Activated partial thromboplastin time</style></keyword><keyword><style  face="normal" font="default" size="100%">Clot waveform analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">D-dimer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1373-1378</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Objectives:&lt;/strong&gt; Patients diagnosed with coronavirus disease (COVID-19) may develop hypercoagulopathy. A thromboelastogram can detect hypercoagulopathy, but it is not commonly available in all healthcare facilities. Understanding the clot waveform analysis (CWA) parameters of the CS-2500 coagulation analyzer in patients diagnosed with COVID-19 may help determine whether it can serve as an alternative. &lt;strong&gt;Methods:&lt;/strong&gt; This study measured the amounts of activated partial thromboplastin time (aPTT)-based CWA, aPTT, plasma prothrombin time (PPT), and D-dimer using the CS-2500 autoanalyzer in 177 patients confirmed with COVID-19 and 110 patients without COVID-19. Retrospective data collection was conducted using electronic medical records. COVID-19 and non-COVID-19 were distinguished by the SARS-COV-2 PCR results.&lt;strong&gt; Results: &lt;/strong&gt;Substantial differences were observed in the aPTT-based CWA parameters, including maximum coagulation velocity (Vmax), maximum coagulation acceleration (Amax), and maximum coagulation deceleration (Dmax) (p = 0.03, p = 0.03, and p = 0.02), between the COVID-19 and non-COVID-19 groups but not between survivors and non-survivors. Additionally, a substantial difference was identified in the D-dimer between the two groups (p = 0.002 and p &amp;lt; 0.001). The difference in D-dimer between both groups could be explained by the fact that non-survivors have a more prominent hypercoagulable state. &lt;strong&gt;Conclusions: &lt;/strong&gt;While the D-dimer may be a better indicator of mortality in COVID-19 patients, the aPTT-based CWA characteristics may be more helpful in differentiating between COVID-19 and non-COVID-19 patients. Further investigations on treatment interference and the specificity of this method to predict hypercoagulable states are warranted.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1373</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Prafa Alif Rahmawan&lt;sup&gt;1&lt;/sup&gt;, Yetti Hernaningsih&lt;sup&gt;2,3*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Student of Specialist, Clinical Pathology Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Clinical Pathology, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sri Nuriana</style></author><author><style face="normal" font="default" size="100%">Balqis</style></author><author><style face="normal" font="default" size="100%">Sukri Palutturi</style></author><author><style face="normal" font="default" size="100%">Indar</style></author><author><style face="normal" font="default" size="100%">Yahya Thamrin</style></author><author><style face="normal" font="default" size="100%">Stang</style></author><author><style face="normal" font="default" size="100%">Anwar Mallongi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of Policy Recommendations in Efforts to Control Positive  COVID-19 Cases in South Sulawesi Province, Indonesia</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Policy</style></keyword><keyword><style  face="normal" font="default" size="100%">Policy Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Surveillance</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">1230-1235</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Inconsistent COVID-19 policies have caused the government to experience a degradation in public trust. So, it is necessary to propose policy recommendations for controlling positive COVID-19 cases that receive support from various multi-sectoral areas. &lt;strong&gt;Method: &lt;/strong&gt;This research was conducted in January–May 2023. This type of research is qualitative-exploratory, using case study methods through indepth interviews and literature studies of all informants. Sampling was purposive sampling. This research variable uses Patton and Sawicki's alternative policy criteria theory (1986). &lt;strong&gt;Results:&lt;/strong&gt; The proposed policy recommendations are increasing COVID-19 vaccine coverage and surveillance for monitoring coronavirus mutations. The two policy recommendations have met technical feasibility because they have clear outcomes, where the outcome of vaccination is to establish herd immunity. In contrast, surveillance of coronavirus mutations has the outcome of analyzing the efficacy of the COVID-19 vaccine. From the economic and financial possibility side, a budget is available with the advantage of carrying out normal activities without any restrictions and efficiency in the health budget. Regarding political viability, the government supports the policy, does not violate the rules, and serves the community's needs. Regarding administrative operability, the government as the authorized party is considered to have adequate capability, organizational support, and institutional commitment. &lt;strong&gt;Conclusion:&lt;/strong&gt; The policy recommendations proposed by policymakers and epidemiology experts are increasing COVID-19 vaccination coverage and monitoring surveillance of coronavirus mutations, and it is hoped that the South Sulawesi Provincial Government can consider the proposed policy recommendations.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1230</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Sri Nuriana&lt;sup&gt;1,*&lt;/sup&gt;, Balqis&lt;sup&gt;2&lt;/sup&gt; , Sukri Palutturi&lt;sup&gt;2&lt;/sup&gt; , Indar&lt;sup&gt;2&lt;/sup&gt; , Yahya Thamrin&lt;sup&gt;3&lt;/sup&gt; , Stang&lt;sup&gt;4&lt;/sup&gt; , Anwar Mallongi&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Student of the Master's Program in Health Administration and Policy, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Health Administration and Policy, Faculty of Public Health, Hasanuddin University Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Occupational Safety and Health, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Population Biostatistics / Family Planning, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chairul A. Nidom</style></author><author><style face="normal" font="default" size="100%">Arif N. M. Ansori</style></author><author><style face="normal" font="default" size="100%">Astria N. Nidom</style></author><author><style face="normal" font="default" size="100%">Setyarina Indrasari</style></author><author><style face="normal" font="default" size="100%">Reviany V. Nidom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Curcumin</style></keyword><keyword><style  face="normal" font="default" size="100%">Indonesia</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular docking</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">228-232</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;COVID-19 has become a global pandemic since 2020. The search for promising drugs based on the abundant herbal ingredients in Indonesia is one of the breakthroughs. Curcumin is a chemical compound with various potentials such as antioxidant, anti-inflammatory and antiviral. We conducted a molecular docking analysis to determine the potential of curcumin against SARS-CoV-2 non-structural and structural proteins, such as the main protease and spike protein. This study used the compound of curcumin (PubChem CID: 969516) from &lt;em&gt;Curcuma longa&lt;/em&gt; L. or turmeric and two Indonesian SARS-CoV-2 isolates that have been deposited in the GISAID database (hCoV-19/Indonesia/JI-PNF-217315/2021 - EPI_ ISL_12777089 or lineage B.1.617.2 and hCoV-19/Indonesia/JI-PNF-211373/2021 - EPI_ISL_6425649 or lineage B.1.470). In addition, we used molnupiravir (PubChem CID: 145996610) as a drug control. We performed molecular docking analysis with PyRx software 0.9.9 (academic license) and visualization of molecular docking results with PyMOL software 2.5.4 (academic license). The results of this study found that curcumin had good potential against main protease and spike protein compared to the drug (control). In summary, we suggested that curcumin is a potential drug candidate against SARS-CoV-2. However, there is a need for future wet laboratory-based pre-clinical research such as &lt;em&gt;in vitro&lt;/em&gt; and &lt;em&gt;in vivo.&lt;/em&gt;&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">228</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Chairul A. Nidom&lt;sup&gt;1,2*&lt;/sup&gt;, Arif N. M. Ansori&lt;sup&gt;1&lt;/sup&gt;, Astria N. Nidom&lt;sup&gt;1,3&lt;/sup&gt;, Setyarina Indrasari1, Reviany V. Nidom&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Professor Nidom Foundation, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, INDONESIA. 3Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Amelia Lorensia</style></author><author><style face="normal" font="default" size="100%">Rivan Virlando Suryadinata</style></author><author><style face="normal" font="default" size="100%">Dita Sukmaya Prawitasari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Knowledge and Perception of the Risk of Respiration Disorders in COVID-19 Pandemic in COPD Patient: A Mixed-Method Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COPD</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">knowledge</style></keyword><keyword><style  face="normal" font="default" size="100%">Perception.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">801-810</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Chronic obstructive pulmonary disease (COPD) have a higher risk for COVID-19-related complications. Knowledge and perception will greatly influence the behavior of a COPD patient in dealing with a problem, such as the risk of COVID-19 infection. The purpose of the study was to determine knowledge and perceptions about the risk of respiration disorders during the COVID-19 pandemic in COPD patients. This research was a mixed methods research with an explanatory sequential research design. The location was conducted in Rungkut District in Surabaya City, East Java, from May-October 2022. Sampling by purposive sampling method, and analyzed descriptively. The research sample was 116 people. On the knowledge, the most correct answers were the COVID-19 virus was contagious (112 of 116). On the perception, the answer with the most positive level is a question regarding the use of masks. Some respondents had a low knowledge category (54 of 116), and the most positive perception category (57 of 116). The respondents' knowledge of the COVID-19 virus showed COVID-19 virus was a contagious disease and was transmitted through air. But many respondents didn’t know about the type of COVID-19 virus. Therefore, it was necessary to develop a strategy to increase knowledge about COVID-19 and related COPD treatment.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><section><style face="normal" font="default" size="100%">801</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Amelia Lorensia&lt;sup&gt;1,*&lt;/sup&gt;, Rivan Virlando Suryadinata&lt;sup&gt;2&lt;/sup&gt;, Dita Sukmaya Prawitasari&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Pharmacy, University of Surabaya, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, University of Surabaya, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Medicine, University of Surabaya, Indonesia.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Etty Hary Kusumastuti</style></author><author><style face="normal" font="default" size="100%">Priangga Adi Wiratama</style></author><author><style face="normal" font="default" size="100%">Grace Ariani</style></author><author><style face="normal" font="default" size="100%">Stephanie Natasha Djuanda</style></author><author><style face="normal" font="default" size="100%">Alphania Rahniayu</style></author><author><style face="normal" font="default" size="100%">Nila Kurniasari</style></author><author><style face="normal" font="default" size="100%">Dyah Fauziah</style></author><author><style face="normal" font="default" size="100%">Anny Setijo Rahaju</style></author><author><style face="normal" font="default" size="100%">Isnin Anang Marhana</style></author><author><style face="normal" font="default" size="100%">Alfian Nur Rosyid</style></author><author><style face="normal" font="default" size="100%">Dwi Wahyu</style></author><author><style face="normal" font="default" size="100%">Gilang Muhammad Setyo Nugroho</style></author><author><style face="normal" font="default" size="100%">Adhitri Anggoro</style></author><author><style face="normal" font="default" size="100%">I Komang Rusgi Yandi</style></author><author><style face="normal" font="default" size="100%">Bambang Pujo Semedi</style></author><author><style face="normal" font="default" size="100%">Jilientasia Godrace Lilihata</style></author><author><style face="normal" font="default" size="100%">Ummi Maimunah</style></author><author><style face="normal" font="default" size="100%">Supriadi</style></author><author><style face="normal" font="default" size="100%">Achmad Lefi</style></author><author><style face="normal" font="default" size="100%">Lalu Galih Pratama Rinjani</style></author><author><style face="normal" font="default" size="100%">Edi Suyanto</style></author><author><style face="normal" font="default" size="100%">Ricardo Ardian Nugraha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Differences in interleukin-6 and interleukin-17 expression in covid-19 post-mortem lung tissue biopsy compared with noncovid- 19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-17</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-6</style></keyword><keyword><style  face="normal" font="default" size="100%">Post mortem lung tissue.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">887-892</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; COVID-19 has spread rapidly around the world. It is necessary to study lung tissue of postmortem COVID19 patients to determine the molecular alteration particularly the role of IL-6 and IL-17 in causing fatality. &lt;strong&gt;Objective:&lt;/strong&gt; This study aims to determine the differences in the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients compared to non-COVID-19 patients. This study also aimed to analyze the correlation between the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients. Methods: This research is an observational analytic study with crosssectional approach. The samples were 15 paraffin blocks of post-mortem lung tissue biopsy of COVID-19 patients, and 15 paraffin blocks of inflammatory lung tissue biopsy or surgery of non-COVID-19 patients. IL-6 and IL-17 expressions were evaluated by immunohistochemical procedure. &lt;strong&gt;Result: &lt;/strong&gt;There was a significant difference in the expression of IL-6 in the COVID-19 group and the non-COVID-19 group with a p-value = 0.001 (p &amp;lt; 0.05). There was a significant difference in the expression of IL-17 in the COVID-19 group and the non-COVID-19 group with p-value = 0.001 (p &amp;lt; 0.05). There was a significant correlation between the expressions of IL-6 and IL-17 in the COVID-19 group, with the Spearman coefficient value (rs) of 0.548 with p = 0.034 (p &amp;lt; 0.05).&lt;strong&gt; Conclusion:&lt;/strong&gt; There are differences in the expression of IL-6 and IL-17 between COVID-19 and non-COVID-19 lung tissue. There is a significant correlation between the expressions of IL-6 and IL-17 in post-mortem lung tissue of COVID-19 patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">887</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Etty Hary Kusumastuti&lt;sup&gt;1,*&lt;/sup&gt;, Priangga Adi Wiratama&lt;sup&gt;1&lt;/sup&gt;, Grace Ariani&lt;sup&gt;1&lt;/sup&gt;, Stephanie Natasha Djuanda&lt;sup&gt;1&lt;/sup&gt;, Alphania Rahniayu&lt;sup&gt;1&lt;/sup&gt;, Nila Kurniasari&lt;sup&gt;1&lt;/sup&gt;, Dyah Fauziah1, Anny Setijo Rahaju&lt;sup&gt;1&lt;/sup&gt;, Isnin Anang Marhana&lt;sup&gt;2&lt;/sup&gt;, Alfian Nur Rosyid&lt;sup&gt;2&lt;/sup&gt;, Dwi Wahyu&lt;sup&gt;2&lt;/sup&gt;, Gilang Muhammad Setyo Nugroho&lt;sup&gt;2&lt;/sup&gt;, Adhitri Anggoro&lt;sup&gt;2&lt;/sup&gt;, I Komang Rusgi Yandi&lt;sup&gt;2&lt;/sup&gt; Bambang Pujo Semedi&lt;sup&gt;3&lt;/sup&gt;, Jilientasia Godrace Lilihata&lt;sup&gt;3&lt;/sup&gt;, Ummi Maimunah&lt;sup&gt;4&lt;/sup&gt;, Supriadi&lt;sup&gt;4&lt;/sup&gt;, Achmad Lefi&lt;sup&gt;5&lt;/sup&gt;, Lalu Galih Pratama Rinjani&lt;sup&gt;5&lt;/sup&gt;, Edi Suyanto&lt;sup&gt;6&lt;/sup&gt;, Ricardo Ardian Nugraha&lt;sup&gt;6&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Forensics and Medicolegal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thi-Lien Nguyen</style></author><author><style face="normal" font="default" size="100%">Huong Ha Thi Thanh</style></author><author><style face="normal" font="default" size="100%">Kiet Ngo Tuan</style></author><author><style face="normal" font="default" size="100%">Doan Cao Son</style></author><author><style face="normal" font="default" size="100%">Thao Le Quang</style></author><author><style face="normal" font="default" size="100%">Hang Nguyen Thi</style></author><author><style face="normal" font="default" size="100%">Tien Vuong Duy</style></author><author><style face="normal" font="default" size="100%">Quyen Doan Thi Tam</style></author><author><style face="normal" font="default" size="100%">Huan Le Quang</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of Antiviral Effects and Toxicity of Herbal Medicine Vipdervir Capsules</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antiviral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">H5N1</style></keyword><keyword><style  face="normal" font="default" size="100%">Herbal</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">681-689</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Antiviral vaccine is not effective, synthetic antiviral drugs are highly toxic, leading to increased interest in herbal medicines as promising antiviral drugs. Recently, Vipdervir has been developed from medicinal herbs with the aim to support and treat diseases caused by viruses such as H5N1 and SARSCoV- 2. In the present study, we assessed Vipdervir's antiviral activity against H5N1 and SARS-CoV-2. In addition, we also evaluated the acute toxicity and repeated dose toxicity of Vipdervir in mice and rabbits, respectively. &lt;strong&gt;Methods&lt;/strong&gt;: H5N1 inhibitory effect of Vipdervir was assessed using hemagglutination inhibition assay. Vipdervir's SARS-CoV-2 inhibitory effect was evaluated by Plaque Reduction Neutralization assay. Acute and repeated dose oral toxicities of Vipdervir were determined according to OECD 423 and OECD 407 guidelines, respectively. &lt;strong&gt;Results:&lt;/strong&gt; Data show that Vipdervir is effective against both H5N1 and SARSCoV- 2. At concentrations of 3 mg/mL and 5 mg/mL Vipdervir completely inhibits H5N1. At a concentration of 50 μg/mL Vipdervir showed an inhibitory effect on SARS-CoV-2. Acute toxicity data revealed that the LD50 of Vipdervir is greater than 35200 mg/kg, b.wt. in mice. Repeated toxicity data indicated that Vipdervir did not induce significant differences in body weight gain, hematology and clinical biochemistry in compared to the control group. The No Observed Adverse Effect Level of Vipdervir is greater than 613.8 mg/kg b.wt./day in rabbits. No delayed toxicity effects of Vipdervir were observed. &lt;strong&gt;Conclusion&lt;/strong&gt;: Vipdervir capsules were found to be antiviral effective and relatively safe in the tested doses and experimental conditions.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><accession-num><style face="normal" font="default" size="100%">27</style></accession-num><section><style face="normal" font="default" size="100%">681</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Thi-Lien Nguyen&lt;sup&gt;1,*&lt;/sup&gt;, Huong Ha Thi Thanh&lt;sup&gt;2&lt;/sup&gt;, Kiet Ngo Tuan&lt;sup&gt;3&lt;/sup&gt;, Doan Cao Son&lt;sup&gt;1&lt;/sup&gt;, Thao Le Quang&lt;sup&gt;1&lt;/sup&gt;, Hang Nguyen Thi&lt;sup&gt;1&lt;/sup&gt;, Tien Vuong Duy&lt;sup&gt;1&lt;/sup&gt;, Quyen Doan Thi Tam&lt;sup&gt;4&lt;/sup&gt;, Huan Le Quang&lt;sup&gt;5,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;National Institute of Drug Quality Control, 48-Hai Ba Trung st., Hoan Kiem dist., Ha Noi city, VIETNAM.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Institute of Natural Products Chemistry, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet st., Cau Giay dist., Ha Noi city, VIETNAM.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;University of Science and Technology of Hanoi, 18-Hoang Quoc Viet st., Cau Giay dist., Ha Noi city, VIETNAM.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;High School for Gifted Students, Hanoi University of Science, 182- Luong The Vinh St., Thanh Xuan dist., Ha Noi city, VIETNAM.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet st., Cau Giay dist., Ha Noi city, VIETNAM.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nala Mawaddani</style></author><author><style face="normal" font="default" size="100%">Ekris Sutiyanti</style></author><author><style face="normal" font="default" size="100%">Muhammad Hermawan Widyananda</style></author><author><style face="normal" font="default" size="100%">Viol Dhea Kharisma</style></author><author><style face="normal" font="default" size="100%">Dora Dayu Rahma Turista</style></author><author><style face="normal" font="default" size="100%">Muhammad Badrut Tamam</style></author><author><style face="normal" font="default" size="100%">Vikash Jakhmola</style></author><author><style face="normal" font="default" size="100%">Syamsurizal</style></author><author><style face="normal" font="default" size="100%">Bayu Ramadhani Fajri</style></author><author><style face="normal" font="default" size="100%">Muhammad Raffi Ghifari</style></author><author><style face="normal" font="default" size="100%">Muhammad Thoriq Albari</style></author><author><style face="normal" font="default" size="100%">Muhammad Arya Ghifari</style></author><author><style face="normal" font="default" size="100%">Amalia Putri Lubis</style></author><author><style face="normal" font="default" size="100%">Dony Novaliendry</style></author><author><style face="normal" font="default" size="100%">Dwi Hilda Putri</style></author><author><style face="normal" font="default" size="100%">Fadhilah Fitri</style></author><author><style face="normal" font="default" size="100%">Devni Prima Sari</style></author><author><style face="normal" font="default" size="100%">Alexander Patera Nugraha</style></author><author><style face="normal" font="default" size="100%">ANM Ansori</style></author><author><style face="normal" font="default" size="100%">Maksim Rebezov</style></author><author><style face="normal" font="default" size="100%">Rahadian Zainul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">In Silico Study of Entry Inhibitor from Moringa oleifera Bioactive Compounds against SARS-CoV-2 Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Active site</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Moringa oleifera</style></keyword><keyword><style  face="normal" font="default" size="100%">Mpro</style></keyword><keyword><style  face="normal" font="default" size="100%">RdRp</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">565-574</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The aim of this study is to screen the content of bioactive compounds of &lt;em&gt;Moringa oleifera &lt;/em&gt;and to identify its potential as an antiviral against COVID 19 through an entry inhibitor mechanism using bioinformatics tools. The sample was obtained from PubChem database. Amino acis sequences were obtained from the NCBI. Protein modeling is made through the SWISSMODEL site. The target proteins for this study were SARS-CoV-2 M&lt;sup&gt;pro&lt;/sup&gt; and RdRp. The protein-inhibitory interaction of the drug from &lt;em&gt;M. oleifera&lt;/em&gt; bioactive compounds to SARS-CoV-2 was predicted by molecular docking with PyRx software. The result shows that&lt;em&gt; M. oleifera &lt;/em&gt;was a potential antiviral candidate for SARS-CoV-2 with an entry inhibitor mechanism through a compound, especially quercetin. The RFMS value of both interactions between M&lt;sup&gt;pro &lt;/sup&gt;and quercetion and RdRp with quercetin were not higher than 1.05. This result still needed further research to prove this prediction.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">565</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Nala Mawaddani&lt;sup&gt;1&lt;/sup&gt;, Ekris Sutiyanti&lt;sup&gt;2&lt;/sup&gt;, Muhammad Hermawan Widyananda&lt;sup&gt;1&lt;/sup&gt;, Viol Dhea Kharisma&lt;sup&gt;3&lt;/sup&gt;, Dora Dayu Rahma Turista&lt;sup&gt;4&lt;/sup&gt;, Muhammad Badrut Tamam&lt;sup&gt;5&lt;/sup&gt;, Vikash Jakhmola&lt;sup&gt;6&lt;/sup&gt;, Syamsurizal&lt;sup&gt;7,8&lt;/sup&gt;, Bayu Ramadhani Fajri&lt;sup&gt;7,9&lt;/sup&gt;, Muhammad Raffi Ghifari&lt;sup&gt;7,10&lt;/sup&gt;, Muhammad Thoriq Albari&lt;sup&gt;7,10&lt;/sup&gt;, Muhammad Arya Ghifari&lt;sup&gt;7,10&lt;/sup&gt;, Amalia Putri Lubis&lt;sup&gt;7,11&lt;/sup&gt;, Dony Novaliendry&lt;sup&gt;7,12&lt;/sup&gt;, Dwi Hilda Putri&lt;sup&gt;7,8&lt;/sup&gt;, Fadhilah Fitri&lt;sup&gt;7&lt;/sup&gt;,&lt;sup&gt;13&lt;/sup&gt;, Devni Prima Sari&lt;sup&gt;7,14&lt;/sup&gt;, Alexander Patera Nugraha&lt;sup&gt;15&lt;/sup&gt;, ANM Ansori&lt;sup&gt;16&lt;/sup&gt; , Maksim Rebezov&lt;sup&gt;17,18,19&lt;/sup&gt;, Rahadian Zainul&lt;sup&gt;7,11,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Malang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Tropical Biology, Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, INDONESIA&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Biology Education Department, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Biology, Faculty of Sciences and Technology, Universitas Muhammadiyah Lamongan, Lamongan, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Center for Advanced Material Processing, Artificial Intelligence, and Biophysics Informatics (CAMP-BIOTICS), Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Department of Biology, Faculty of Mathematics and Natural Sciences Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;9&lt;/sup&gt;Information Technology, Dapartement of Electronic, Faculty of Engineering, Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;10&lt;/sup&gt;Department of Information Technology, Faculty of Computer Sciences, Universitas Brawijaya, Malang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;11&lt;/sup&gt;Department of Chemistry, Faculty of Mathematics and Natural Sciences Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;12&lt;/sup&gt;Program Study Informatics, Faculty of Engineering, Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;13&lt;/sup&gt;Department of Statistics, Faculty of Mathematics and Natural Sciences Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;14&lt;/sup&gt;Department of Mathematics, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;15&lt;/sup&gt;Department of Orthodontics, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, INDONESIA. 16Professor Nidom Foundation, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;17&lt;/sup&gt;Department of Scientific Research, Russian State Agrarian University - Moscow Timiryazev Agricultural Academy, Moscow, RUSSIAN FEDERATION&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;Faculty of Biotechnology and Food Engineering, Ural State Agrarian University, Yekaterinburg, RUSSIAN FEDERATION&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;Department of Scientific Research, K.G. Razumovsky Moscow State University of Technologies and Management (The First Cossack University), Moscow, RUSSIAN FEDERATION&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dewintha Airene Novianti</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Massive Pleural Effusion with Adenosine Deaminase (ADA) Test Positive and COVID-19 Confirmed: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADA test</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Pleural effusion</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Tb pleuritis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">450-454</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;A 26-year-old man complained of shortness of breath for 3 days before the hospital admission. The patient had a history of coughing up blood and had consumed alcohol and drugs. Decreased vesicular auscultation and dull percussion in the left lateral pulmo. Laboratory result showed increased neutrophil-lymphocyte ratio C-reactive protein, D-dimer, procalcitonin, ferritin, and decreased albumin level. Pleural fluid analysis indicated the presence of exudate, SARS-CoV-2 PCR positive, and increased ADA level to 43 U/L. Based on the examination results, we suspected that the etiology of the massive pleural effusion was tuberculous pleurisy, particularly due to increased ADA levels. The patient was diagnosed with COVID-19 pneumonia with massive pleural effusion and tuberculous pleurisy. Massive pleural effusion in SARS-CoV-2 infection is rare. Thus, laboratory modalities for massive pleural effusion diagnosis are needed to determine the etiology and effective treatment for the patient. ADA analysis could be considered as an initial examination in patients with pleural effusion during the wait for pleural fluid culture results.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">28</style></accession-num><section><style face="normal" font="default" size="100%">450</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dewintha Airene Novianti&lt;sup&gt;1&lt;/sup&gt;, Puspa Wardhani &lt;sup&gt;2,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga /Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faratisha IFD</style></author><author><style face="normal" font="default" size="100%">Cahyono AW</style></author><author><style face="normal" font="default" size="100%">Erwan NE</style></author><author><style face="normal" font="default" size="100%">Putri AM</style></author><author><style face="normal" font="default" size="100%">Ariel DG</style></author><author><style face="normal" font="default" size="100%">Yunita KC</style></author><author><style face="normal" font="default" size="100%">Nugraha RYB</style></author><author><style face="normal" font="default" size="100%">Mardhiyyah K</style></author><author><style face="normal" font="default" size="100%">Fitri LE</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Potential Effect of Nigericin from Streptomyces hygroscopicus subsp. Hygroscopicus Against the Syndemic of Malaria and COVID-19 through Molecular Docking Perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular docking</style></keyword><keyword><style  face="normal" font="default" size="100%">Nigericin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">268-275</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Malaria is a constantly challenging problem, notably in the Coronavirus Disease-19 (COVID-19) pandemic. The syndemic condition, malaria-COVID-19 co-infections, had been reported. Our previous study successfully revealed several compounds from&lt;em&gt; Streptomyces hygroscopicus s&lt;/em&gt;ubsp. Hygroscopicus, including nigericin that has both antimalarial and antiviral effects. In malaria infection, &lt;em&gt;Plasmodium falciparum &lt;/em&gt;Chloroquine Resistance Transporter (PfCRT) is the potential target for eliminating &lt;em&gt;Plasmodium.&lt;/em&gt; Meanwhile, for SARS-CoV-2 infection, MPro is an essential protein for SARS-CoV-2 survival. This research aims to examine the potential effect of nigericin towards&lt;em&gt; Plasmodium&lt;/em&gt; and SARS-CoV-2 by assessing its molecular interaction with PfCRT and MPro through molecular docking study.&lt;strong&gt; Methods: &lt;/strong&gt;The protein target PfCRT and MPro were obtained from Protein Data Bank. Nigericin and the control ligand (chloroquine and N3) were obtained from PubChem. The pharmacokinetic analysis was done using SwissADME. Specific molecular docking was conducted using PyRx 0.9 and was visualized using LigPlot and PyMOL. &lt;strong&gt;Results:&lt;/strong&gt; Nigericin has a large molecular weight, leading to the non-fulfillment of the Lipinski rule for oral administration. Through molecular docking study, the binding affinity of the Nigericin-PfCRT complex was -8.1 kcal/mol, and Nigericin-MPro was -8.6 kcal/mol. These binding affinities were stronger than the control ligand. The interaction between Nigericin-PfCRT and Nigericin-MPro share a similar pocket-site and amino acid residues as the control ligands. &lt;strong&gt;Conclusion: &lt;/strong&gt;Nigericin has potential antimalarial and anti-coronavirus effects through molecular docking perspective by assessing the binding affinity and similarity of amino acid residues compared to control. Administration of systemic route can be an option in giving nigericin.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">268</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Faratisha IFD&lt;sup&gt;1&lt;/sup&gt;, Cahyono AW&lt;sup&gt;1,2&lt;/sup&gt;, Erwan NE&lt;sup&gt;1,3&lt;/sup&gt;, Putri AM&lt;sup&gt;1,3&lt;/sup&gt;, Ariel DG&lt;sup&gt;1&lt;/sup&gt;, Yunita KC&lt;sup&gt;1&lt;/sup&gt;, Nugraha RYB&lt;sup&gt;1,4&lt;/sup&gt;, Mardhiyyah K&lt;sup&gt;1,2,5&lt;/sup&gt;, Fitri LE&lt;sup&gt;1,4&lt;/sup&gt;,*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Malaria Research Group, Faculty of Medicine, Universitas Brawijaya, Malang 65145, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Doctoral Program in Medical Science, Faculty of Medicine, Universitas Brawijaya, Malang 65145, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Master Program in Biomedical Science, Faculty of Medicine, Universitas Brawijaya, Malang 65145, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, 65145 Malang, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Biochemistry &amp;amp; Biomolecular, Faculty of Medicine, Universitas Brawijaya, 65145 Malang, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yosua Butar Butar</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thalassemia β Major in Confirmed Covid-19 Patient: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Preventable Death</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalassemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">445-449</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The incidence of Thalassemia with confirmed Covid 19 is very rare. The aim of this study is to know the prognosis and evaluate the management of therapy in thalassemia β Mayor patients with COVID-19. This case study describes the progression of Thalassemia β Mayor with COVID 19 starting from how to establish the diagnosis of Thalassemia β Mayor and COVID 19 until how to treat thalassemia β Mayor patients with COVID-19 This case study result describes that COVID 19 aggravates thalassemia β Mayor. Infection can adversely affect thalassemia. Giving Blood transfusions must be done due to anemia in Thalassemia, but it will have an impact on the accumulation of iron in the body which will increase the severity of the infection. The administration of iron-chelation drugs is beneficial for Covid but on the other hand, it is contraindicated in Thalassemia patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">27</style></accession-num><section><style face="normal" font="default" size="100%">445</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Yosua Butar Butar&lt;sup&gt;1,*&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;F1Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maslichah Mafruchati</style></author><author><style face="normal" font="default" size="100%">Jonathan Makuwira</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Number of research papers about Agricultural production, Meat, and Egg During COVID-19 Pandemic: Does it Changed than Before?</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Agricultural production</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Egg</style></keyword><keyword><style  face="normal" font="default" size="100%">Meat</style></keyword><keyword><style  face="normal" font="default" size="100%">Research papers</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">July 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">995-998</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;COVID-19 pandemic limits many physical activities of the society in public areas. The agricultural production sector is one of the important sectors in supporting the country’s nutrition demand. Research is a way to maintain the productivity of the agricultural sector. This study has a purpose to analyze if pandemic COVID-19 has an impact on the number of papers about agriculture recorded by Scopus. This study uses a quantitative with secondary data analysis approach in collecting data. The samples are paper on the Scopus website contains keywords “agriculture&amp;amp; meat”, and “agriculture&amp;amp;egg”. the period of samples are during 2019-2020. The data are analyzed using Vosviewer software to show the institution with the most related topic paper. The result shows that some papers are decreasing while others are increase based on the document type. For paper related to “agriculture” meat”, article as full type research paper increases along with review type paper. For a paper about “agriculture &amp;amp; egg”, conference type paper and review increase, while other decreases. It can be concluded that the type of paper along with the topic affects the institutions’ productivity in publishing papers&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">995</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Maslichah Mafruchati&lt;sup&gt;1,&lt;/sup&gt;*, Jonathan Makuwira&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Veterinary Anatomy, Faculty of Veterinary Medicine (60115), Universitas Airlangga, Mulyorejo, C Campus, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Malawi University of Science and Technology, 5196, Limbe, MALAWI.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Noha Abd Alkareem Younis Younis</style></author><author><style face="normal" font="default" size="100%">Rania Mohammad Hamam</style></author><author><style face="normal" font="default" size="100%">Amal Mayyas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Online Survey: Prevalence and Attitude of Jordanians Towards Using Herbal Remedies in the Pandemic COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Botanicals.</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Herbal immunomodulators</style></keyword><keyword><style  face="normal" font="default" size="100%">Herbal remedies</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemic</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">1632-1638</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Coronavirus disease 2019 (COVID-19) is a new virus caused by SARS-CoV-2, a coronavirus from the coronavirus family, that can provoke severe respiratory syndrome. The disease became a pandemic in December 2019. Impaired immune modulation is one of the processes implicated in its pathogenesis, which contributes to poor COVID-19 outcomes. Many investigations have been conducted using medication to control coronaviral infections as antiviral agents or immunomodulators. The results of these tests, however, demonstrated that these medications were useless in fighting the disease. Some people believe that using herbal immunomodulators can aid in the prevention or even curing of COVID-19. Based on prior research, in the management of COVID-19, several botanicals may be useful. We go over the patient attitude and benefits of using such herbal remedies in the regimen of treating COVID-19 in Jordan.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1632</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Noha Abd Alkareem Younis Younis&lt;sup&gt;1&lt;/sup&gt;, Rania Mohammad Hamam&lt;sup&gt;2&lt;/sup&gt;,*, Amal Mayyas&lt;sup&gt;3&lt;/sup&gt;,*&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmacy, Al Balqa Applied University, Aqaba Universal College, Aqaba, JORDAN.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pharmacy, Princess Sarvath Community College, Amman, JORDAN.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Pharmacy, Faculty of Health Sciences, American University of Madaba, Madaba, JORDAN.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ehab M Mostafa</style></author><author><style face="normal" font="default" size="100%">Mohammed Gamal</style></author><author><style face="normal" font="default" size="100%">Mohammed M Ghoneim</style></author><author><style face="normal" font="default" size="100%">Shaimaa Hussein</style></author><author><style face="normal" font="default" size="100%">Ahmed H El-Ghorab</style></author><author><style face="normal" font="default" size="100%">Mohamed A Abdelgawad</style></author><author><style face="normal" font="default" size="100%">Arafa Musa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Repurposing of FDA Approved Alkaloids as COVID 19 Inhibitors; in silico Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alkaloids</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Docking study</style></keyword><keyword><style  face="normal" font="default" size="100%">FDA</style></keyword><keyword><style  face="normal" font="default" size="100%">Natural drugs</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">110-123</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Alkaloid drugs were permitted for using as a treatment of numerous diseases. Colchicine, codeine, piperine, papaverine, ergometrine, theophylline, theobromine and caffeine are recognized safe alkaloids and used for many human disfunctions. The chemical structures of alkaloids have flexible chemical moieties with various electronic and chemical characters. COVID-19 is a horrible disease as result from that the discovering of potent drugs from previously FDA approved drugs is the main objective of this study. &lt;strong&gt;Methods:&lt;/strong&gt; docking studies were used for discovering the interactions of alkaloids with protease proteins. The nature of selected alkaloids structures was utilized for advance insights studies to predict new medical applications. &lt;strong&gt;Results: &lt;/strong&gt;Docking studies for alkaloids were completed and the obtained outcomes, displayed that all tried alkaloids have great attraction with the five protease proteins, the energy docking score ranged from -2.9516 (for colchicine with 5R82) to -24.7449 (for ergotamine with 5R80) kcal/mol with 1-5 variable interactions bond. &lt;strong&gt;Conclusion: &lt;/strong&gt;Among the tested drugs, papaverine and ergometrine revealed high docking scores for all five proteins (score ranged from, -14.1058 to 23.1619 for papaverine and, -4.7900 to 24.7449 for ergometrine) and number of interactions with all tested proteins are two to three for papaverine but for ergometrine are two to five.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">110</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Ehab M. Mostafa&lt;sup&gt;1&lt;/sup&gt;, Mohammed Gamal&lt;sup&gt;2&lt;/sup&gt;, Mohammed M. Ghoneim&lt;sup&gt;3&lt;/sup&gt;, Shaimaa Hussein&lt;sup&gt;4&lt;/sup&gt;, Ahmed H. El-Ghorab&lt;sup&gt;5&lt;/sup&gt;, Mohamed A. Abdelgawad&lt;sup&gt;2,&lt;/sup&gt;*, Arafa Musa&lt;sup&gt;1&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Pharmacognosy Department, College of Pharmacy, Jouf University, Sakaka, Aljouf, 72341, KSA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, 72341, KSA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Pharmacy, College of Pharmacy, Al Maarefa University, Ad Diriyah 13713, SAUDI ARABIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, SAUDI ARABIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Chemistry Department, College of Science, Jouf university, Sakaka, Aljouf 72341, SAUDI ARABIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">T  Sudhakar Johnson</style></author><author><style face="normal" font="default" size="100%">D. B. Anantha Narayana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of Spices in Offering Natural Immunity to Fight Various Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Diet</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Nutrition</style></keyword><keyword><style  face="normal" font="default" size="100%">Spices</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">600-613</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Adequate nutrition intake is one of main factors to strengthen immunity. Traditional and cultural practices of food consumption involve use of several spices in limited quantities as part of food. Spices have offered versatile biological effects due to presence of valuable biochemicals. The aim of the present paper is to review published scientific evidence on potential role of spices in offering innate and adaptive immunity to human body. It has been demonstrated that, turmeric, one of the widely used spices, acts as an anti-viral agent through inhibition of viral entry into cells, suppression of viral replication and modulation of cytokines. A field study revealed that nations with higher consumption of spices have shown lesser COVID-19 cases and higher recovery rates. Further, spices also have shown to possess antioxidant activity superior or equivalent to ascorbic acid and are known to regulate inflammation processes. Evidence generated from the published literature is compelling to arrive at a conclusion that consumption of spices might improve immunity there by offering protection against various diseases including COVID-19. It is also noted that there are lesser number of human clinical trials in this area which warrants immediate attention to provide scientific evidence to immunity offered by spices.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">600</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;T. Sudhakar Johnson&lt;sup&gt;1&lt;/sup&gt;, D. B. Anantha Narayana&lt;sup&gt;2,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Technical and Regulatory, Viridis Biopharma Pvt Ltd, Govandi, Mumbai-400 043, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Chief Scientific Officer, Ayurvidye Trust, and Chairman, Scientific Panel, Nutraceuticals, Food Safety Standards Authority of India (FSSAI), Ministry of Health and Family Welfare, INDIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdullahi Temitope Jamiu</style></author><author><style face="normal" font="default" size="100%">Christiana Eleojo Aruwa</style></author><author><style face="normal" font="default" size="100%">Ismail Abiodun Abdulakeem</style></author><author><style face="normal" font="default" size="100%">Abdulwakeel Ayokunnun Ajao</style></author><author><style face="normal" font="default" size="100%">Saheed SABIU</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phytotherapeutic Evidence Against Coronaviruses and Prospects for COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antivirals</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug target</style></keyword><keyword><style  face="normal" font="default" size="100%">Natural products</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant metabolites</style></keyword><keyword><style  face="normal" font="default" size="100%">Plants</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">September 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1252-1267</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The emergence of the novel β-coronavirus (SARS-CoV-2) and subsequent outbreak of COVID-19, is a global health challenge with no known treatment to date and has culminated in significant morbidity and mortality. This article highlights current understanding on SARSCoV- 2 based on the available scientific evidence on human coronavirus (HCoV) infections, which could offer novel insights and therapeutic targets for SARS-CoV-2, the causative agent of COVID-19. Specifically, the paper presents available phytotherapeutic evidence against pathogenic HCoVs with a view to identifying potent plant-derived antiviral agents that could be developed to aid the fight against coronaviruses and the current COVID-19. Evidently, elucidation of CoV integral proteins such as the spike protein, angiotensin-converting enzyme 2, 3C-like cysteine protease and papain-like protease, as good targets for drug developments has lent credence to the use of medicinal plants or their metabolites as prophylaxis or treatment interventions in CoV infections and holds promising ground for SARS-CoV-2. While some promising phytocompounds are currently under clinical trials for COVID-19, increased research into plants and in-depth characterization of their metabolites could reveal more interesting results that would benefit humanity in its fight against emerging and re-emerging viral infections including the current COVID-19. Overall, given the current body of evidence on the potential development of phytotherapeutics for COVID-19, fears need to be allayed while clinical trials continue. Conclusively, the lockdown and other preventive measures which have been implemented in most parts of the world should be humanely exercised and supported to ensure compliance and safety of lives.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1252</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Abdullahi Temitope Jamiu&lt;sup&gt;2&lt;/sup&gt;, Christiana Eleojo Aruwa&lt;sup&gt;1&lt;/sup&gt;, Ismail Abiodun Abdulakeem&lt;sup&gt;3,&lt;/sup&gt; Abdulwakeel Ayokun-nun Ajao&lt;sup&gt;4&lt;/sup&gt; and Saheed Sabiu&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Biotechnology and Food Technology, Durban University of Technology, P.O. Box 1334, Durban, 4000, SOUTH AFRICA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Microbial, Biochemical and Food Technology, University of the Free State, Bloemfontein 9300, SOUTH AFRICA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Biological Sciences, Al- Hikmah University, Ilorin, NIGERIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Botany and Plant Biotechnology, University of Johannesburg, P.O. Box 524, Auckland Park APK, 2006, SOUTH AFRICA.&lt;/p&gt;
</style></auth-address></record></records></xml>